What Investors Should Know About Medpace CEO Troendle Selling $10 Million in Stock
Troendle retains a $3.27 billion combined stake, representing 19% of the market cap, with the majority of holdings controlled through Medpace Investors, LLC.
August J. Troendle, CEO of Medpace Holdings, sold 15,978 shares of the company's common stock, generating a transaction value of $10 million. According to the SEC Form 4 filing, the weighted average sale price per share was $623.93. At the market close on August 24, 2026, the post-transaction value per share was $620.03. Medpace Holdings, a leading contract research organization, operates with a workforce of 6,500 employees and delivers integrated clinical development services worldwide.
The company has reported impressive financials, with TTM revenue of $2.8 billion and net income of $491.5 million, highlighting the high demand for its outsourcing capabilities. Medpace's success is attributed to its extensive service portfolio, operational scale, and strong relationships with pharmaceutical and biotechnology clients in various therapeutic areas.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
